Regeneron Pharmaceuticals said it will acquire "substantially all" of 23andMe's assets. The genetic testing company filed for Chapter 11 bankruptcy protection in March.

The consumer privacy ombudsman in 23andMe’s sale of customers’ genetic data is defending his choice of counsel against ...

A U.S. bankruptcy judge has cleared 23andMe’s $305 million sale to TTAM Research, a nonprofit led by co-founder Anne Wojcicki ...

Regeneron will not acquire 23andMe's Lemonaid Health telehealth business. "We have deep experience with large-scale data management," Regeneron co-founder George Yancopoulos said in a statement.

Genetic testing company 23andMe can proceed with a $305 million sale to the company’s co-founder Anne Wojcicki after a U.S.

Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

SALT LAKE CITY (KUTV) — Utah families who used 23andMe's genetic testing services face unique privacy risks as the biotech company enters bankruptcy proceedings and prepares for sale to pharmaceutical ...

Regeneron Pharmaceuticals on Monday announced it is buying 23andMe out of bankruptcy for $256 million – taking with it the company’s extensive trove of genetic samples and data.

Regeneron, the Tarrytown, New York-based pharmaceutical company, agreed to purchase 23andMe for $256 million, following the saliva test kit company's bankruptcy in March.. The company plans to ...

Regeneron's co-founder, Dr. George D. Yancopoulos, who is also the company's president and chief scientific officer, described the 23andMe acquisition as part of Regeneron's strategy to use DNA to ...

Regeneron, the Tarrytown, New York-based pharmaceutical company, agreed to purchase 23andMe for $256 million, following the saliva test kit company's bankruptcy in March.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.